Promotion of colorectal cancer invasion and metastasis through activation of NOTCH–DAB1–ABL–RHOGEF protein TRIO

Cancer Discovery

Volumn 5, Issue 2, 2015, Pages 198-211

  Sonoshita, Masahiro ^a,e   Itatani, Yoshiro ^a,f   Kakizaki, Fumihiko ^a   Sakimura, Kenji ^b   Terashima, Toshio ^c   Katsuyama, Yu ^d   Sakai, Yoshiharu ^a   Taketo, M Mark ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL] AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL) PYRAZOLO [3, 4 D] PYRIMIDINE; ABELSON KINASE; DASATINIB; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IMATINIB; NOTCH RECEPTOR; PEPTIDES AND PROTEINS; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; TRIO PROTEIN; UNCLASSIFIED DRUG; DAB1 PROTEIN, HUMAN; DAB1 PROTEIN, MOUSE; NERVE PROTEIN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRIO PROTEIN, HUMAN; TRIO PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; METASTASIS; MOUSE; MUTAGENESIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANIMAL; COLORECTAL TUMOR; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; COLORECTAL NEOPLASMS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MICE; NEOPLASM METASTASIS; NERVE TISSUE PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, NOTCH; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; SIGNAL TRANSDUCTION;

EID: 84922369531     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0595     Document Type: Article

References (54)

1. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8.
2. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. New Engl J Med 2009; 361: 2449-60.
3. Sonoshita M, Aoki M, Fuwa H, Aoki K, Hosogi H, Sakai Y, et al. Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 2011; 19: 125-37.
4. Spano D. Molecular networks that regulate cancer metastasis. Semin Cancer Biol 2012; 22: 234-49.
5. Hashimoto-Torii K, Torii M, Sarkisian MR, Bartley CM, Shen J, Radtke F, et al. Interaction between Reelin and Notch signaling regulates neuronal migration in the cerebral cortex. Neuron 2008; 60: 273-84.
6. Li Y, Hibbs MA, Gard AL, Shylo NA, Yun K. Genome-wide analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of Wnt, SHH, and Hippo pathway effectors by Notch1. Stem Cells 2012; 30: 741-52.
7. Krejci A, Bernard F, Huusden BE, Collins S, Bray SJ. Direct response to Notch activation: signaling crosstalk and incoherent logic. Sci Signal 2009; 2: 1-14.
8. Sanada K, Gupta A. Disabled-1-regulated adhesion of migrating neurons to radial glial fiber contributes to neuronal positioning during early corticogenesis. Neuron 2004; 42: 197-211.
9. Dowell RD. Transcription factor binding variation in the evolution of gene regulation. Trends Genet 2010; 26: 468-75.
10. Howell BW, Gertler FB, Cooper JA. Mouse disabled (mDab1): a Src binding protein implicated in neuronal development. EMBO J 1997; 19: 121-32.
11. Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 2010; 3: re6.
12. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Molcellbio 2004; 5: 33-44.
13. Arnaud L, Ballif BA, Förster E, Cooper JA. Fyn tyrosine kinase is a critical regulator of Disabled-1 during brain development. Curr Biol 2003; 13: 9-17.
14. Barilá D, Mangano R, Gonfloni S, Kretzchmar J, Moro M, Bohmann D, et al. A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK. EMBO J 2000; 19: 273-81.
15. Forsthoefel DJ, Liebl EC, Kolodziej PA, Seeger MA. The Abelson tyrosine kinase, the Trio GEF and Enabled interact with the Netrin receptor Frazzled in Drosophila. Development 2005; 132: 1983-94.
16. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev 2009; 28: 5-14.
17. Weinberg RA. Moving out: invasion and metastasis. The Biology of Cancer. 2nd ed. New York: Garland Science; 2014. p. 587- 654.
18. Debant A, Serra-Pagès C, Seipel K, O'Brien S, Tang M, Park S-H, et al. The multidomain protein Trio binds the LAR transmembrane tyrosine phophatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Proc Natl Acad Sci U S A 1996; 93: 5466-71.
19. Sekine A, Fujiwara M, Narumiya S. Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. J Biol Chem 1989; 264: 8602-5.
20. Narumiya S, Ishizaki K, Uehata M. Use and properties of ROCKspecific inhibitor Y-27632. Methods Enzymol 2000; 325: 273-84.
21. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 2004; 101: 7618-23.
22. Blom N, Gammeltoft S, Brunak S. Sequence- and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999; 295: 1351-62.
23. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003- 7.
24. Ramalingam S, Baughtridge GW, Johnston MJ, Gracz AD, Magness ST. Distinct levels of Sox9 expression mark colon epithelial stem cells that form colonoids in culture. Am J Physiol Gastrointest Liver Physiol 2012; 302: G10-20.
25. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with propertieses of stem cells. Cell 2008; 133: 704-15.
26. Chen X, Halberg RB, Burch RP, Dove WR. Intestinal adenomagenesis involves core molecular signatures of the epithelial-mesenchymal transition. J Mol Histol 2008; 39: 283-94.
27. Friedl P, Locker J, Sahai E, Segall E. Classifying collective cancer cell invasion. Nat Cell Biol 2012; 14: 777-83.
28. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Darygina EI, et al. Compensation mechanism in tumor cell migration: mesencymal- amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003; 160: 267-77.
29. Croft DR, Olson MF. Regulating the conversion between rounded and elongated modes of cancer cell movement. Cancer Cell 2008; 14: 349- 51.
30. Ridley A. Rho GTPases and cell migration. J Cell Sci 2001; 114: 2713-22.
31. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003; 5: 711-9.
32. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008; 135: 510-23.
33. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marchal JF, Harrington K, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for Rho GTPases in leading and following cells. Nat Cell Biol 2007; 9: 1392-400.
34. Reffay M, Parrini MC, Cohet-Escartin O, Ladoux B, Buguin A, Coscoy S, et al. Interplay of RhoA and mechanical forces in collective cell migration driven by leader cells. Nat Cell Biol 2014; 16: 217- 23.
35. Friedl P. Prespecification and plasticity: shifting mechanism of cell migration. Curr Opin Cell Biol 2004; 16: 14-23.
36. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis- Tsakonas S, et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435: 964-8.
37. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, et al. Modulation of Notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-58.
38. VanDussen KL, Carulli AJ, Keeley TM, Patel SR, Puthoff BJ, Magness ST, et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development 2012; 139: 488-97.
39. Bellone G, Ferrero D, Carbone A, DeQuadros MR, Gramigni C, Prati A, et al. Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol Ther 2004; 3: 385-92.
40. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 2006; 169: 2054-65.
41. Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, et al. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevascizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs 2014; 32: 330-9.
42. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci U S A 1995; 92: 4482-6.
43. el Marjou F, Jansen KP, Chang BH, Li M, Hindie V, Chan L, et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004; 39: 186-93.
44. Han H, Tanigaki K, Yamamoto N, Kuroda K, Yoshimoto M, Nakahata T, et al. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int Immunol 2002; 14: 637-45.
45. Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. BBA 2001; 1551: M11-8.
46. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J Biol Chem 1996; 274: 695-701.
47. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001; 293: 876-80.
48. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
49. Nosaka T, Kwashima T, Misawa K, Ikuta K, Mui AL-F, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoiesis. EMBO J 1999; 18: 4754-65.
50. Nellesen DT, Lai EC, Posakony JW. Discrete enhancer elements mediate selective responsiveness of Enhancer of split complex genes to common transcriptional activators. Dev Biol 1999; 213: 33-53.
51. Kakizaki F, Aoki K, Miyoshi H, Carrasco N, Aoki M, Taketo MM. CDX transcription factors positively regulate expression of solute carrier family 5, member 8 in the colonic epithelium. Gastroenterology 2010; 138: 627- 35.
52. Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990; 18: 5322.
53. Bellanger J-M, Lazaro J-B, Diriong S, Fernandez A, Lamb N, Debant A. The two guanine nucleotide exchange factor domains of Trio link the Rac1 and the RhoA pathways in vivo. Oncogene 1998; 16: 147-52.
54. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett 1977; 407: 313-9.